Content Block Tag: NRG-GY007

‘NRG-GY007: A Phase I/II Study of Ruxolitinib with Front-line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer’ of page ‘NRG-GY007’

Principal Investigator/Co-Principal Investigator Robert A. Burger, M.D./Charles N. Landon, Jr., M.D. Primary Objective Phase I – Determine whether treatment with ruxolitinib in combination with conventional neoadjuvant and post-surgical chemotherapy is safe and tolerable in the primary therapy for epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.Phase II – Demonstrate whether treatment with ruxolitinib in combination […]

Read More

‘NRG-GY007 Documentation’ of page ‘NRG-GY007’

Amendment 3 Documents This study is currently limited to Phase I Safety Lead-in participants. Summary:  Clarifications to assure that patients who discontinue protocol therapy are followed to determine if they undergo interval tumor reductive surgery as per the secondary endpoint in Sec 15.8.1; In Secs 4.2.1 and 4.2.2, Pre-treatment and During Treatment Assessment columns have […]

Read More